Munich
Germany
19
2026-04-09
The entities that hold a legal rights for patent applications filed by inventor Strupp Michael:
Michael Strupp from Munich, DE has applied for patents for these inventions. The list has both pending applications and granted patents:
ACETYL LEUCINE FOR USE IN TREATING NIEMANN-PICK DISEASE TYPE C
#2 | 2026-01-29PHARMACEUTICAL COMPOSITIONS AND USES DIRECTED TO LYSOSOMAL STORAGE DISORDERS
#3 | 2025-10-30ACETYL-LEUCINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION
#4 | 2024-06-20PHARMACEUTICAL COMPOSITIONS AND USES DIRECTED TO LYSOSOMAL STORAGE DISORDERS
#5 | 2024-06-13THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES
#6 | 2023-11-02ACETYL-LEUCINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION
#7 | 2023-09-14Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
#8 | 2023-07-06THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES
#9 | 2023-06-29THE COMBINATION OF ACETYL LEUCINE AND 4-AMINOPYRIDINE OR ACETAZOLAMIDE FOR TREATING ATAXIA
#10 | 2023-02-16TREATMENT OF LATE-ONSET NEURODEGENERATIVE DISEASES IN HETEROZYGOUS NPC1 GENE MUTATION CARRIERS
#11 | 2022-11-17COMBINATION THERAPY WITH ACETYL-LEUCINE AND MIGLUSTAT
#12 | 2022-10-20PHARMACEUTICAL COMPOSITIONS AND USES DIRECTED TO LYSOSOMAL STORAGE DISORDERS
#13 | 2021-11-25Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
#14 | 2021-04-15Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
#15 | 2021-03-25Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
#16 | 2020-08-13Treatment for migraine
#17 | 2020-06-11Therapeutic agents for neurodegenerative diseases
#18 | 2019-07-04Pharmaceutical compositions and uses directed to lysosomal storage disorders
#19 | 2019-03-21Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
2456970 ⎘